Dopamine Signaling Pathway is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Dopamine signaling is a critical neurotransmitter system in the central nervous system (CNS) that regulates movement, motivation, reward, cognition, and neuroendocrine function. Dopamine (DA) acts through five G protein-coupled receptors (D1-D5) organized into two main families: D1-like (D1, D5) that stimulate adenylyl cyclase, and D2-like (D2, D3, D4) that inhibit it.
Dopamine biosynthesis follows the pathway:
- Tyrosine → L-DOPA: Tyrosine hydroxylase (TH), the rate-limiting enzyme, converts tyrosine to L-DOPA
- L-DOPA → Dopamine: Aromatic L-amino acid decarboxylase (AADC) converts L-DOPA to dopamine
- Storage: Dopamine is packaged into synaptic vesicles by vesicular monoamine transporter 2 (VMAT2)
| Enzyme |
Function |
Gene |
| Tyrosine hydroxylase (TH) |
Rate-limiting step |
TH |
| Aromatic L-amino acid decarboxylase (AADC) |
Converts L-DOPA to DA |
DDC |
| VMAT2 |
Vesicular packaging |
SLC18A2 |
| Monoamine oxidase (MAO) |
Dopamine degradation |
MAOA/MAOB |
| COMT |
Dopamine degradation |
COMT |
- D1 Receptor (DRD1):Gs-coupled, increases cAMP, found in striatum, cortex, nucleus accumbens
- D5 Receptor (DRD5):Gs-coupled, highest affinity for dopamine, found in hippocampus, cortex
- D2 Receptor (DRD2):Gi-coupled, decreases cAMP, exists as short (D2S)2L) isoforms and long (D
- D3 Receptor (DRD3):Gi-coupled, highly expressed in limbic system
- D4 Receptor (DRD4):Gi-coupled, polymorphisms associated with ADHD
flowchart TD
DA[Dopamine] --> D1R[D1/D5 Receptor] -->
D1R --> Gs[G_s protein] -->
Gs --> AC[Adenylyl Cyclase] -->
AC --> cAMP[↑ cAMP]
cAMP --> PKA[PKA Activation] -->
PKA --> CREB[CREB Phosphorylation] -->
CREB --> GeneTrans[Gene Transcription] -->
PKA --> DARPP32[DARPP-32] -->
DARPP32 --> PP1[PP1 Inhibition]
flowchart TD
DA[Dopamine] --> D2R[D2/D3/D4 Receptor] -->
D2R --> Gi[G_i protein] -->
Gi --> AC[Adenylyl Cyclase Inhibition] -->
AC --> cAMP[↓ cAMP] -->
Gi --> BetaArrestin[β-arrestin pathway] -->
BetaArrestin --> ERK[ERK/MAPK]
- Origin: Substantia nigra pars compacta (SNc)
- Target: Striatum (caudate, putamen)
- Function: Motor control, habit formation
- Degeneration in: Parkinson's disease
- Origin: VTA
- Target: Nucleus accumbens, amygdala, hippocampus
- Function: Reward, motivation, addiction
- Dysregulation in: Addiction, schizophrenia
- Origin: VTA
- Target: Prefrontal cortex
- Function: Cognition, working memory
- Dysregulation in: Schizophrenia, ADHD
- Origin: Hypothalamus
- Target: Pituitary gland
- Function: Prolactin inhibition
- Loss of dopaminergic neurons in SNc
- Treatment: L-DOPA, dopamine agonists, MAO-B inhibitors, deep brain stimulation
- Hyperactive mesolimbic pathway (positive symptoms)
- Hypoactive mesocortical pathway (negative symptoms, cognitive deficits)
- Treatment: D2 receptor antagonists (antipsychotics)
- Dysregulation of prefrontal cortical dopamine signaling
- Treatment: Stimulants (methylphenidate, amphetamines)
- Enhanced mesolimbic dopamine signaling
- Downregulation of D2 receptors with chronic exposure
| Target |
Drug Class |
Examples |
| D2 receptors |
Agonists |
Pramipexole, ropinirole |
| D2 receptors |
Antagonists |
Haloperidol, risperidone |
| MAO-B |
Inhibitors |
Selegiline, rasagiline |
| COMT |
Inhibitors |
Entacapone, tolcapone |
| Dopamine reuptake |
Inhibitors |
Methylphenidate |
| Dopamine release |
Agents |
Amphetamines |
The study of Dopamine Signaling Pathway has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Beaulieu JM, Gainetdinov RR. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev. 2011
- Zhong H, et al. Dopamine signaling and addiction. Annu Rev Psychol. 2021
- Kalia LV, Lang AE. Parkinson's disease. Lancet. 2015
- Howes OD, et al. Dopamine synthesis capacity in schizophrenia. Am J Psychiatry. 2012
- Volkow ND, et al. Dopamine in drug addiction. Neuron. 2009
- Greengard P. The neurobiology of dopamine signaling. Biosci Rep. 2001
- Missale C, et al. Dopamine receptors: from structure to function. Physiol Rev. 1998
- Sibley DR. New insights into dopaminergic receptors. Mol Interv. 2003
🔴 Low Confidence
| Dimension |
Score |
| Supporting Studies |
8 references |
| Replication |
0% |
| Effect Sizes |
25% |
| Contradicting Evidence |
0% |
| Mechanistic Completeness |
50% |
Overall Confidence: 29%